



(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/44 (2006.01)
A61P 25/28 (2006.01) A61K 39/00 (2006.01)
C07K 16/28 (2006.01) C07K 16/18 (2006.01)

(21) International Application Number:

PCT/EP2024/064691

(22) International Filing Date:

29 May 2024 (29.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2023/064623
31 May 2023 (31.05.2023) EP
PCT/EP2023/079276
20 October 2023 (20.10.2023) EP
PCT/EP2024/055668
05 March 2024 (05.03.2024) EP


(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).

(72) Inventors: **ABRANTES, João André**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **AG-NEW, David Andrew**; Hexagon Place 6 Falcon Way, Shire Park, Welwyn Garden City Greater London AL7 1TW (GB). **ALCARAZ, Fabien**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **CRONEY, Ruth Emma**; Hexagon Place 6 Falcon Way, Shire Park, Welwyn Garden City Greater London AL7 1TW (GB). **HOFFMANN, Carsten**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **JORDAN, Paul**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **KLEIN, Gregory**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **KULIC, Luka**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **MARCHESI, Maddalena**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **VOGT, Annamarie**; c/o F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel (CH). **SVOBO-**

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(54) Title: THERAPEUTIC USE OF BISPECIFIC ANTI-ABETA/TFR ANTIBODIES

Figure 5



(57) Abstract: Herein is reported a bispecific antibody specifically binding to human Abeta protein and human transferrin receptor (bispecific anti-Abeta/TfR antibody) as well as the use of such bispecific antibodies as a medicament in the treatment of Alzheimer's Disease, including where the bispecific antibody is administered intravenously at a dose of 0.2 mg/kg to 7.2 mg/kg once every four weeks.

[Continued on next page]

DA, Hanno; c/o Roche Diagnostics GmbH, Nonnenwald 2,
82377 Penzberg (DE).

**(74) Agent: SKOLAUT, Dr. Alexander // Roche Diagnostics
GmbH, Patentabteilung;** Nonnenwald 2, 82377 Penzberg
(DE).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE